The global response to the antimicrobial resistance crisis has seen success using incentives to attract new specialty companies into the scientifically difficult and commercially unattractive infectious disease space, but now the young crop of sponsors with late-stage candidates must overcome a challenging regulatory environment in the US – and not all can be expected to succeed.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?